Top Markets
Coin of the day
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation

ADMP
株式のランク #38725
Adamis Pharmaceuticals Corporation is a specialized biopharmaceutical company... Adamis Pharmaceuticals Corporation is a specialized biopharmaceutical company primarily engaged in the development and commercialization of products within the United States, targeting key therapeutic domains such as allergy, opioid overdose, respiratory conditions, and inflammatory diseases. Its current product portfolio includes SYMJEPI pre-filled epinephrine syringes for the emergency treatment of severe allergic reactions, including anaphylaxis; dry powder inhaler products designed for asthma management; and injectable naloxone for addressing opioid overdose. Additionally, Adamis is advancing pipeline candidates such as APC400, a tempol gel aimed at mitigating radiation-induced dermatitis in cancer patients, and APC410, formulated to treat a range of respiratory ailments including asthma, respiratory syncytial virus (RSV), influenza, and COVID-19. The company also extends its offerings to include corticosteroids, hormone replacement therapies, hospital outsourcing products, and other injectables, alongside a line of veterinary pharmaceutical products. Established in 2006, Adamis Pharmaceuticals Corporation maintains its headquarters in San Diego, California.
株価
$0.6241
最終同期: 2023-10-03
時価総額
$836.88K
変化(1日)
-2.10%
変化(1年)
0.00%
US
取引 Adamis Pharmaceuticals Corporation (ADMP)

カテゴリー

Adamis Pharmaceuticals Corporation(ADMP)の利益
2026 時点の利益 TTM: 0
Adamis Pharmaceuticals Corporation の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Adamis Pharmaceuticals Corporation の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。